Search Orphan Drug Designations and Approvals
-
Generic Name: | recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b |
---|---|
Date Designated: | 06/29/2016 |
Orphan Designation: | Treatment of gastric cancer including cancer of the gastroesophageal junction. |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Five Prime Therapeutics, Inc. 2 Corporate Drive South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-